Pharma · Gastrointestinal

The newest therapeutic area · In active sponsor evaluations

Perspectum PAIR

The quantitative IBD endpoint your protocol has been missing.

PAIR (Perspectum AI Reader) brings AI pathology into one auditable, central read for IBD trials, with digital endoscopy on the roadmap. Geboes histopathology and our anatomy-anchored scoring stack run today; Mayo and UCEIS endoscopic indices follow as the endoscopy capability lands. Target slide-to-report turnaround of days, not weeks. Built pharma-first; clinical adoption follows the evidence.

PAIR (Perspectum AI Reader) PAIR-MASH vs AIM-MASH, head-to-head

48h slide-to-report turnaround3× faster than central pathology baseline

Emerging-wins pillar, PAIR-IBD first.

An outline of what this page will cover when published.

PAIR-IBD positioning

Next family SKU after PAIR-MASH, pharma-first. Structural opening from imaging-CRO consolidation in IBD trials. Named sponsors and named partnerships are added only where each has been cleared per Section 8.1. Owner: Pharma Solutions (MM). Source: Brand Review v2 A.3, Section 6.3.

Sequencing rule

Evidence pack and DDT-COA submission precede the PAIR-IBD vs AIM-HI UC head-to-head deck, which precedes any marketing spotlight beyond a soft launch. Source: Brand Review v2 Decision 7.

Cardiac inside the page at launch

Cardiac evidence stack runs underneath until it stands up as a standalone TA page. Heimdall and cT1-cardiac outcome work referenced. Owner: Translational Science.

Head-to-head deck path

PAIR-IBD vs Path.AI AIM-HI UC gated download under /pharma/ibd-and-cardiac/pair-vs-aim-ibd. Updated quarterly. Same pattern as the PAIR-MASH deck. Source: Brand Review v2 A.6.

Regulator transparency row

PAIR-IBD entry on the /pharma regulator status table once submission dates are named. Honest on what is submitted, accepted, pending. Source: Brand Review v2 A.7.

Proof-band coverage

Scientific, Regulatory, Commercial, Operational, Human. Minimum three of five per Section 8.3.

Gastrointestinal